Concepedia

Margaret E. Gatti‐Mays

ME

Statistics

Publications

32

Citations

2K

H-Index

21

Active since

2016

Affiliations

National Cancer Institute(Current)

National Institutes of Health

Center for Cancer Research

The Ohio State University

Dana-Farber Cancer Institute

Margaret E. Gatti‐Mays is an author at National Cancer Institute specializing in oncology, immunotherapy, and medicine.

Publications per year

2016–2024

32

Publications

32

Current Landscape of Immunotherapy in Breast Cancer

Sylvia Adams, Margaret E. Gatti‐Mays, Kevin Kalinsky et al. · JAMA Oncology · 2019 · 409 citations · Full text

Medicine, Immunology, Oncology +17

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Marijo Bilušić, Christopher R. Heery, Julie Collins et al. · Journal for ImmunoTherapy of Cancer · 2019 · 273 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah et al. · JAMA Oncology · 2021 · 185 citations · Full text

Medicine, Hematology, Oncology +10

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Julius Strauss, Margaret E. Gatti‐Mays, Byoung Chul Cho et al. · Journal for ImmunoTherapy of Cancer · 2020 · 159 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews et al. · Journal for ImmunoTherapy of Cancer · 2019 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 32